UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000603
Receipt number R000000729
Scientific Title Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer
Date of disclosure of the study information 2007/02/09
Last modified on 2017/11/30 18:05:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer

Acronym

Phase II study of paclitaxel plus capecitabine (XP) for metastatic breast cancer

Scientific Title

Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer

Scientific Title:Acronym

Phase II study of paclitaxel plus capecitabine (XP) for metastatic breast cancer

Region

Japan


Condition

Condition

metastatic breast cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to
estimate PFS and examine the execution possibility of weekly paclitaxel/oral capecitabine combination therapy for patient with metastatic breast cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Progression Free Survival (PFS)

Key secondary outcomes

adverse event
overall survival (OS)
Time To Progression (TTF)
Response rate, PFS and OS for breast cancer with ER/PgR/HER2 negative


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

1) Paclitaxel 80mg/m2 (day 1,8 q3W)

2) Capecitabine 1650mg/m2 (day 1-14 followed by a week rest q3W)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Histologically confirmed breast carcinoma.
2. clinically distant metastasis
3. previous teatment is nothing or only 1st line chemotherapy. (but the case, after taxane is prescribed in adjuvant or neo ajuvant 6months or more has elapsed, is the register possible not in addition to 1 regimen)
4. Age>=20
5. PS(ECOG) 0-1
6. Written informed consent
7. expected survival time: more than 6 months
8. Adequate organ function

Key exclusion criteria

1. severe complication
2. The brain metastasis which possesses condition
3. Past history of allergic reaction
4. Past history of allergic reaction to cremophor EL (polyoxyethylated castor oil) or polysorbate
5. which has the use history of taxane or 5' DFUR or capecitabine (but the case, after taxane is prescribed in adjuvant or neo ajuvant 6months or more has elapsed, is the register possible not in addition to 1 regimen).
6. Peripheral neuropathy >= grade 2 in prior chemotherapy
7. Pregnant or lactating women
8. Doctor's decision for exclusion

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshio Tabei

Organization

Saitama Cancer Center

Division name

Endocrinology

Zip code


Address

818 Komuro Ina Kitaadachi, Saitama 362-0806

TEL

048-722-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Toshihiro Kai

Organization

Saitama Breast Cancer Clinical Study Group (SBCCSG)

Division name

Executive office

Zip code


Address

1550 Katayanagi Minuma Ward Saitama City, Saitama 337-0024

TEL

048-686-7155

Homepage URL

http://www.sbccsg.org/

Email

toshikai@sbccsg.org


Sponsor or person

Institute

Saitama Breast Cancer Clinical Study Group (SBCCSG)

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 02 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2007 Year 01 Month 29 Day

Date of IRB


Anticipated trial start date

2007 Year 02 Month 01 Day

Last follow-up date

2008 Year 06 Month 01 Day

Date of closure to data entry

2008 Year 06 Month 01 Day

Date trial data considered complete

2008 Year 06 Month 01 Day

Date analysis concluded

2008 Year 06 Month 01 Day


Other

Other related information



Management information

Registered date

2007 Year 02 Month 08 Day

Last modified on

2017 Year 11 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000729


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name